---
schema_version: "secwatch.filing_event.v1"
accession: "0001641489-23-000019"
form_type: "8-K"
ticker: "VTVT"
cik: "0001641489"
company_name: "vTv Therapeutics Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:13:03.385101+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# vTv Therapeutics Q1 net loss narrows to $4.5M; cash rises to $18.8M; FDA agrees on pediatric study plan for TTP399

## Summary
- Net loss attributable to vTv shareholders was $4.5M ($0.06/share) vs $7.0M ($0.10/share) in Q1 2022.
- Cash and cash equivalents totaled $18.8M as of March 31, 2023, up from $12.1M at year-end 2022, after receiving $12M from G42 Investments.
- R&D expenses increased to $3.9M from $3.1M YoY, driven by TTP399 development costs; G&A expenses decreased to $3.5M from $5.3M.
- FDA agreed with pediatric study plan for TTP399 in type 1 diabetes patients aged 2-16; phase 2 study in type 2 diabetes on insulin therapy being prepared with G42 affiliate.
- Revenue was $0 in Q1 2023 vs $2M in Q1 2022 (prior collaboration revenue ended).

## SEC filing metadata
- accession: 0001641489-23-000019
- form_type: 8-K
- ticker: VTVT
- cik: 0001641489
- company_name: vTv Therapeutics Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641489/000164148923000019/0001641489-23-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641489/000164148923000019/vtvt-20230511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641489-23-000019
- JSON: https://secwatch.observer/filing/0001641489-23-000019.json
- Plain text: https://secwatch.observer/filing/0001641489-23-000019.txt

## Key facts
- Earnings Releases
  vTv Therapeutics Inc. reported the first quarter ended March 31, 2023 results: net income $4.5 million, EPS $0.06 per basic share.
  - Period: the first quarter ended March 31, 2023
  - Net income: $4.5 million
  - EPS: $0.06 per basic share
  - Result: reported results
  source text: Net loss attributable to vTv shareholders for the three months ended March 31, 2023, was $4.5 million or $0.06 per basic share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641489/000164148923000019/0001641489-23-000019-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.